Literature DB >> 15128861

Expression of a poly-glutamine-ataxin-3 transgene in orexin neurons induces narcolepsy-cataplexy in the rat.

Carsten T Beuckmann1, Christopher M Sinton, S Clay Williams, James A Richardson, Robert E Hammer, Takeshi Sakurai, Masashi Yanagisawa.   

Abstract

The sleep disorder narcolepsy has been linked to loss of hypothalamic neurons producing the orexin (hypocretin) neuropeptides. Here, we report the generation of transgenic rats expressing a human ataxin-3 fragment with an elongated polyglutamyl stretch under control of the human prepro-orexin promoter (orexin/ataxin-3 rats). At 17 weeks of age, the transgenic rats exhibited postnatal loss of orexin-positive neurons in the lateral hypothalamus, and orexin-containing projections were essentially undetectable. The loss of orexin production resulted in the expression of a phenotype with fragmented vigilance states, a decreased latency to rapid eye movement (REM) sleep and increased REM sleep time during the dark active phase. Wakefulness time was also reduced during the dark phase, and this effect was concentrated at the photoperiod boundaries. Direct transitions from wakefulness to REM sleep, a defining characteristic of narcolepsy, occurred frequently. Brief episodes of muscle atonia and postural collapse resembling cataplexy were also noted while rats maintained the electroencephalographic characteristics of wakefulness. These findings indicate that the orexin/ataxin-3 transgenic rat could provide a useful model of human narcolepsy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15128861      PMCID: PMC6729432          DOI: 10.1523/JNEUROSCI.5560-03.2004

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  63 in total

1.  Neuropharmacology of Sleep and Wakefulness.

Authors:  Christopher J Watson; Helen A Baghdoyan; Ralph Lydic
Journal:  Sleep Med Clin       Date:  2010-12

2.  Effects of sleep on the cardiovascular and thermoregulatory systems: a possible role for hypocretins.

Authors:  H Schwimmer; H M Stauss; F Abboud; S Nishino; E Mignot; J M Zeitzer
Journal:  J Appl Physiol (1985)       Date:  2010-08-12

Review 3.  Energy expenditure: role of orexin.

Authors:  Jennifer A Teske; Vijayakumar Mavanji
Journal:  Vitam Horm       Date:  2012       Impact factor: 3.421

Review 4.  Orexin receptors: pharmacology and therapeutic opportunities.

Authors:  Thomas E Scammell; Christopher J Winrow
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011       Impact factor: 13.820

5.  Orexins: looking forward to sleep, back at addiction.

Authors:  Thomas E Scammell; Clifford B Saper
Journal:  Nat Med       Date:  2007-02       Impact factor: 53.440

Review 6.  K+ channels stimulated by glucose: a new energy-sensing pathway.

Authors:  Denis Burdakov
Journal:  Pflugers Arch       Date:  2007-01-06       Impact factor: 3.657

Review 7.  Addiction and arousal: the hypocretin connection.

Authors:  Benjamin Boutrel; Luis de Lecea
Journal:  Physiol Behav       Date:  2007-11-22

8.  Oxytocin deficiency mediates hyperphagic obesity of Sim1 haploinsufficient mice.

Authors:  Bassil M Kublaoui; Terry Gemelli; Kristen P Tolson; Yu Wang; Andrew R Zinn
Journal:  Mol Endocrinol       Date:  2008-05-01

9.  Dual orexin actions on dorsal raphe and laterodorsal tegmentum neurons: noisy cation current activation and selective enhancement of Ca2+ transients mediated by L-type calcium channels.

Authors:  K A Kohlmeier; S Watanabe; C J Tyler; S Burlet; C S Leonard
Journal:  J Neurophysiol       Date:  2008-07-30       Impact factor: 2.714

Review 10.  Animal models of sleep disorders.

Authors:  Linda A Toth; Pavan Bhargava
Journal:  Comp Med       Date:  2013-04       Impact factor: 0.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.